Kinase shRNA screening reveals that TAOK3 enhances microtubule-targeted drug resistance of breast cancer cells via the NF-κB signaling pathway.

Abstract

BACKGROUND:

Chemotherapy is currently one of the most effective treatments for advanced breast cancer. Anti-microtubule agents, including taxanes, eribulin and vinca-alkaloids are one of the primary major anti-breast cancer chemotherapies; however, chemoresistance remains a problem that is difficult to solve. We aimed to discover novel candidate protein targets to combat chemoresistance in breast cancer.

METHODS:

A lentiviral shRNA-based high-throughput screening platform was designed and developed to screen the global kinome to find new therapeutic targets in paclitaxel-resistant breast cancer cells. The phenotypes were confirmed with alternative expression in vitro and in vivo. Molecular mechanisms were investigated using global phosphoprotein arrays and expression microarrays. Global microarray analysis was performed to determine TAOK3 and genes that induced paclitaxel resistance.

RESULTS:

A serine/threonine kinase gene, TAOK3, was identified from 724 screened kinase genes. TAOK3 shRNA exhibited the most significant reduction in IC50 values in response to paclitaxel treatment. Ectopic downregulation of TAOK3 resulted in paclitaxel-resistant breast cancer cells sensitize to paclitaxel treatment in vitro and in vivo. The expression of TAOK3 also was correlated to sensitivity to two other anti-microtubule drugs, eribulin and vinorelbine. Our TAOK3-modulated microarray analysis indicated that NF-κB signaling played a major upstream regulation role. TAOK3 inhibitor, CP43, and shRNA of NF-κB both reduced the paclitaxel resistance in TAOK3 overexpressed cells. In clinical microarray databases, high TAOK3 expressed breast cancer patients had poorer prognoses after adjuvant chemotherapy.

CONCLUSIONS:

Here we identified TAOK3 overexpression increased anti-microtubule drug resistance through upregulation of NF-κB signaling, which reduced cell death in breast cancer. Therefore, inhibition of the interaction between TAOK3 and NF-κB signaling may have therapeutic implications for breast cancer patients treated with anti-microtubule drugs. Video abstract.

• Authors: Tsung-Ching Lai, Chih-Yeu Fang, Yi-Hua Jan, Hsiao-Ling Hsieh, Yi-Fang Yang, Chun-Yu Liu, Peter Mu-Hsin Chang, Michael Hsiao
• Journal: Cell communication and signaling : CCS (Cell Commun Signal) Vol. 18 Issue 1 Pg. 164 (10 21 2020) ISSN: 1478-811X [Electronic] England
• PMID: 33087151 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Bridged-Ring Compounds
• NF-kappa B
• RNA, Small Interfering
• Taxoids
• taxane
• Cyclooxygenase 2
• PTGS2 protein, human
• Protein Serine-Threonine Kinases
• TAOK3 protein, human
• Paclitaxel

Topics

• Animals
• Apoptosis (drug effects)
• Breast Neoplasms (genetics, metabolism, pathology)
• Bridged-Ring Compounds (pharmacology)
• Cell Line, Tumor
• Cell Proliferation (drug effects)
• Cyclooxygenase 2 (metabolism)
• Drug Resistance, Neoplasm (drug effects, genetics)
• Female
• Humans
• Kaplan-Meier Estimate
• Mice, Inbred NOD
• Mice, SCID
• Microtubules (metabolism)
• NF-kappa B (metabolism)
• Paclitaxel (pharmacology)
• Prognosis
• Protein Serine-Threonine Kinases (metabolism)
• RNA, Small Interfering (metabolism)
• Signal Transduction
• Taxoids (pharmacology)